Form 4: Crescent BioPharma COO Boosts Stake with RSU and Options

Crescent BioPharma's President and COO, Jonathan McNeill, reported the acquisition of 25,507 Restricted Stock Units and options for 78,029 ordinary shares.

Summary

• Jonathan McNeill, President and COO of CRESCENT BIOPHARMA, INC. (CBIO), reported changes in his beneficial ownership.
• Acquired 19,507 Ordinary Shares through Restricted Stock Units (RSUs) on December 15, 2025.
• Acquired an additional 6,000 Ordinary Shares through Restricted Stock Units (RSUs) on December 15, 2025.
• Acquired Stock Options (right to buy) for 78,029 Ordinary Shares on December 15, 2025, with an exercise price of $13.21.
• Following these transactions, Mr. McNeill beneficially owns 159,707 Ordinary Shares directly.
• He also beneficially owns 78,029 Stock Options directly.
• The RSUs will vest in approximately equal three-month installments over four years from December 15, 2025, contingent on continuous employment.
• The Stock Options will vest with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, also contingent on continuous employment, and expire on December 15, 2035.

Sentiment

Score: 6

Explanation: The filing reports executive compensation awards, which are generally viewed as a positive sign of management's commitment and alignment with shareholder interests, though it does not provide operational or financial performance data.

Positives

• Increased insider ownership through equity awards aligns management's interests with shareholders.
• The awards demonstrate the company's commitment to retaining and incentivizing key executives.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate a long-term commitment from the President and COO to the company's future performance and growth, contingent on his continuous employment.

Industry Context

Equity-based compensation, such as Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate executive talent, aligning their incentives with long-term shareholder value creation.

Related Party Transactions

• The acquisition of Restricted Stock Units and Stock Options by Jonathan McNeill, President and COO, represents executive compensation awards from the issuer.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with long-term shareholder value through equity ownership.
• Employees: Reinforces the company's strategy of using equity compensation to incentivize key personnel.

Next Steps

• Vesting of 25,507 Restricted Stock Units in approximately equal three-month installments through December 15, 2029, subject to continuous employment.
• Vesting of 78,029 Stock Options at a rate of 1/48th per month through December 15, 2029, subject to continuous employment.

Key Dates

Keywords

Crescent BioPharma, CBIO, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Beneficial Ownership